Head to Head Comparison: Inotiv (NASDAQ:NOTV) versus Alseres Pharmaceuticals (OTCMKTS:ALSE)

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Inotiv (NASDAQ:NOTV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Institutional and Insider Ownership

18.2% of Inotiv shares are held by institutional investors. 8.9% of Alseres Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Inotiv shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Inotiv”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Inotiv	$513.02 million	0.04	-$68.62 million	($2.22)	-0.25

Alseres Pharmaceuticals has higher earnings, but lower revenue than Inotiv.

Profitability

This table compares Alseres Pharmaceuticals and Inotiv’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Inotiv	-13.38%	-17.15%	-3.39%

Analyst Ratings

This is a breakdown of current ratings for Alseres Pharmaceuticals and Inotiv, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Inotiv	1	0	1	0	2.00

Inotiv has a consensus price target of $3.00, suggesting a potential upside of 445.26%. Given Inotiv’s stronger consensus rating and higher possible upside, analysts clearly believe Inotiv is more favorable than Alseres Pharmaceuticals.

Summary

Inotiv beats Alseres Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.